Gal-1 (Galectin-1) Upregulation Contributes to Abdominal Aortic Aneurysm Progression by Enhancing Vascular Inflammation
OBJECTIVE:Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside–binding lectin constitutivel...
Saved in:
Published in | Arteriosclerosis, thrombosis, and vascular biology Vol. 41; no. 1; pp. 331 - 345 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Lippincott Williams & Wilkins
01.01.2021
American Heart Association, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | OBJECTIVE:Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside–binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression.
APPROACH AND RESULTS:Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)–infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls.
CONCLUSIONS:Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA. |
---|---|
AbstractList | Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside-binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. Approach and Results: Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)-infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP (mitogen-activated protein) kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls.OBJECTIVEAbdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside-binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. Approach and Results: Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)-infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP (mitogen-activated protein) kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls.Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA.CONCLUSIONSGal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA. Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside-binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. Approach and Results: Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)-infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP (mitogen-activated protein) kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls. Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA. OBJECTIVE:Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no prognostic and therapeutic target is available for disease management. Gal-1 (galectin-1) is a β-galactoside–binding lectin constitutively expressed in vasculature with roles in maintaining vascular homeostasis. This study aims to investigate the potential involvement of Gal-1 in AAA progression. APPROACH AND RESULTS:Gal-1 was significantly elevated in circulation and aortic tissues of Ang II (angiotensin II)–infused apoE-deficient mice developing AAA. Gal-1 deficiency reduced incidence and severity of AAA with lower expression of aortic MMPs (matrix metalloproteases) and proinflammatory cytokines. TNFα (tumor necrosis factor alpha) induced Gal-1 expression in cultured vascular smooth muscle cells and adventitial fibroblasts. Gal-1 deletion enhanced TNFα-induced MMP9 expression in fibroblasts but not vascular smooth muscle cells. Cysteinyl-labeling assay demonstrated that aortic Gal-1 exhibited susceptibility to oxidation in vivo. Recombinant oxidized Gal-1 induced expression of MMP9 and inflammatory cytokines to various extents in macrophages, vascular smooth muscle cells, and fibroblasts through activation of MAP kinase signaling. Clinically, serum MMP9 level was significantly higher in both patients with AAA and coronary artery disease than in control subjects, whereas serum Gal-1 level was elevated in patients with AAA but not coronary artery disease when compared with controls. CONCLUSIONS:Gal-1 is highly induced and contributes to AAA by enhancing matrix degradation activity and inflammatory responses in experimental model. The pathological link between Gal-1 and AAA is also observed in human patients. These findings support the potential of Gal-1 as a disease biomarker and therapeutic target of AAA. |
Author | Chiang, Ming-Tsai Chen, Yen-Hui Hsu, Fu-Fei Chau, Lee-Young Tsai, Min-Shao Huang, Po-Hsun Liu, Fu-Tong Chen, I-Ming Hsu, Yaw-Wen Chen, Ying-Hwa Chen, Jaw-Wen Leu, Hsin-Bang |
AuthorAffiliation | Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) Division of Cardiovascular Surgery, Department of Surgery (I.-M.C.), Taipei Veterans General Hospital, Taiwan |
AuthorAffiliation_xml | – name: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) – name: Division of Cardiovascular Surgery, Department of Surgery (I.-M.C.), Taipei Veterans General Hospital, Taiwan – name: Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.). Division of Cardiovascular Surgery, Department of Surgery, National Yang-Ming University, Taipei, Taiwan. (I.-M.C.) Division of Healthcare and Management, Healthcare Center, National Yang-Ming University, Taipei, Taiwan. (H.-B.L.) Division of Cardiology, Department of Internal Medicine, National Yang-Ming University, Taipei, Taiwan. (P.-H.H., J.-W.C., Ying-Hwa Chen) Taipei Veterans General Hospital, Taiwan. School of Medicine, National Yang-Ming University, Taipei, Taiwan. (H.-B.L., Ying-Hwa Chen) Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan. (P.-H.H.) Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan. (J.-W.C.) |
Author_xml | – sequence: 1 givenname: Ming-Tsai surname: Chiang fullname: Chiang, Ming-Tsai organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) – sequence: 2 givenname: I-Ming surname: Chen fullname: Chen, I-Ming organization: Division of Cardiovascular Surgery, Department of Surgery (I.-M.C.), Taipei Veterans General Hospital, Taiwan – sequence: 3 givenname: Fu-Fei surname: Hsu fullname: Hsu, Fu-Fei organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) – sequence: 4 givenname: Yen-Hui surname: Chen fullname: Chen, Yen-Hui organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) – sequence: 5 givenname: Min-Shao surname: Tsai fullname: Tsai, Min-Shao organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) – sequence: 6 givenname: Yaw-Wen surname: Hsu fullname: Hsu, Yaw-Wen organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) – sequence: 7 givenname: Hsin-Bang surname: Leu fullname: Leu, Hsin-Bang organization: Division of Healthcare and Management, Healthcare Center (H.-B.L.), Taipei Veterans General Hospital, Taiwan – sequence: 8 givenname: Po-Hsun surname: Huang fullname: Huang, Po-Hsun organization: Division of Cardiology, Department of Internal Medicine (P.-H.H., J.-W.C., Ying-Hwa Chen), Taipei Veterans General Hospital, Taiwan – sequence: 9 givenname: Jaw-Wen surname: Chen fullname: Chen, Jaw-Wen organization: Division of Cardiology, Department of Internal Medicine (P.-H.H., J.-W.C., Ying-Hwa Chen), Taipei Veterans General Hospital, Taiwan – sequence: 10 givenname: Fu-Tong surname: Liu fullname: Liu, Fu-Tong organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) – sequence: 11 givenname: Ying-Hwa surname: Chen fullname: Chen, Ying-Hwa organization: Division of Cardiology, Department of Internal Medicine (P.-H.H., J.-W.C., Ying-Hwa Chen), Taipei Veterans General Hospital, Taiwan – sequence: 12 givenname: Lee-Young surname: Chau fullname: Chau, Lee-Young organization: Division of Cardiovascular Research, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan (M.-T.C., F.-F.H., Yen-Hui Chen, M.-S.T., Y.-W.H., F.-T.L., L.-Y.C.) |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33147994$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kktvGyEUhVGVqnm0f6CLimW6wOExzGM5tdIkUqR0kWSLGGBsWgZcYGT53xfHzqYLL7iXK53vSJfDJTjzwRsAvhK8IKQmN_3z64_-vl8QiheMcNa1H8AF4bRCVc3qs3LHTYd4XdFzcJnSb4xxRSn-BM4ZI1XTddUF2N5Jhwi8Ls2obD0i3-HLJprV7GS2wcNl8DnaYc4mwRxgP-gwWS8d7EPMVsHemznu0gR_xbCKJqU9NOzgrV9Lr6xfwVeZVHGL8MGPTk7Tm-9n8HGULpkvx34FXn7ePi_v0ePT3cOyf0SKdbxFQ6M6rTUeOFej1JI2StW6aUZMZdsqiluuTDsUyUiNxpqolqhSR0X0oCRjV-D64LuJ4e9sUhaTTco4J70JcxK04k1XNx3vivTbUToPk9FiE-0k4068P1YRtAeBiiGlaEahbH7bJkdpnSBY7HMRx1xEyUUcciko_Q99dz8J1QdoG1w2Mf1x89ZEsTbS5fVpsDoB7r8BqzFHFFOCSRlROYyyf8mns8c |
CitedBy_id | crossref_primary_10_1096_fj_202301832RR crossref_primary_10_3390_biom12020339 crossref_primary_10_4196_kjpp_2022_26_5_347 crossref_primary_10_1016_j_autrev_2022_103258 crossref_primary_10_1080_15384101_2022_2124489 crossref_primary_10_12998_wjcc_v12_i21_4717 crossref_primary_10_1042_BST20200677 crossref_primary_10_1038_s41392_023_01325_7 crossref_primary_10_1111_jcmm_16757 crossref_primary_10_3389_fcvm_2021_753095 crossref_primary_10_1016_j_mvr_2024_104754 crossref_primary_10_1080_15384101_2022_2094577 crossref_primary_10_3390_diagnostics12010183 crossref_primary_10_1002_smll_202402141 crossref_primary_10_1016_j_jep_2021_114845 crossref_primary_10_2174_011573403X274886231227111902 crossref_primary_10_1126_sciadv_abm7322 crossref_primary_10_1097_CD9_0000000000000097 crossref_primary_10_1155_2022_4766987 |
Cites_doi | 10.1073/pnas.1609019113 10.1161/01.ATV.0000143384.69170.2d 10.1371/journal.pone.0001774 10.1073/pnas.0603883103 10.1016/j.ajpath.2012.09.022 10.1042/CS20030189 10.1093/glycob/cwu008 10.4049/jimmunol.0803164 10.1016/S0021-9258(19)50024-2 10.1161/01.atv.20.12.2527 10.1161/ATVBAHA.110.206573 10.1016/s0304-4165(02)00313-6 10.1523/JNEUROSCI.4483-03.2004 10.4049/jimmunol.1701172 10.1111/febs.13634 10.1016/j.jvs.2006.04.047 10.1159/000025625 10.1038/s41598-018-29843-3 10.1007/BF02978209 10.1101/cshperspect.a011254 10.1038/sj.onc.1204950 10.3389/fphar.2010.00009 10.1152/ajplung.00192.2006 10.1016/j.imlet.2010.03.010 10.1172/JCI38308 10.1016/j.biopha.2009.09.008 10.1161/CIRCRESAHA.112.270520 10.1126/science.6367039 10.1016/j.jtcvs.2011.07.053 10.1074/jbc.M205698200 10.1016/s1471-4906(02)02232-9 10.1161/01.ATV.0000085631.76095.64 10.1161/01.CIR.0000058700.41738.12 10.1016/j.ejvs.2005.10.030 10.1046/j.1432-1033.2000.01311.x 10.1093/glycob/cwl025 10.1146/annurev-med-101712-174206 10.1038/s41598-018-22135-w 10.1161/01.ATV.0000214999.12921.4f 10.1165/ajrcmb.23.1.4014 10.1016/s0008-6363(99)00276-x 10.1165/ajrcmb.20.4.3420 10.1056/NEJMcp1401430 10.1038/nrcardio.2017.52 10.1291/hypres.30.1015 10.1161/01.CIR.0000165117.71483.0C |
ContentType | Journal Article |
Copyright | Lippincott Williams & Wilkins 2020 American Heart Association, Inc. |
Copyright_xml | – notice: Lippincott Williams & Wilkins – notice: 2020 American Heart Association, Inc. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1161/ATVBAHA.120.315398 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1524-4636 |
EndPage | 345 |
ExternalDocumentID | 33147994 10_1161_ATVBAHA_120_315398 10.1161/ATVBAHA.120.315398 00043605-202101000-00032 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .Z2 01R 0R~ 1J1 23N 2WC 40H 4Q1 4Q2 4Q3 5GY 5RE 5VS 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AARTV AASCR AASOK AAXQO ABASU ABBUW ABDIG ABJNI ABPXF ABQRW ABVCZ ABXVJ ABZAD ABZZY ACDDN ACEWG ACGFS ACGOD ACILI ACLDA ACPRK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADGGA ADHPY AE6 AENEX AFBFQ AFDTB AFUWQ AGINI AHMBA AHOMT AHQNM AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC AYCSE BAWUL BOYCO BQLVK C45 CS3 DIK DIWNM E.X E3Z EBS EEVPB ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FRP GNXGY GQDEL GX1 H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B O9- OAG OAH OB2 OL1 OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OWW OWY OXXIT P2P PQQKQ PZZ RAH RIG RLZ S4R S4S TEORI TR2 TSPGW V2I VVN W3M W8F WOQ WOW X3V X3W YFH .3C .55 .GJ 3O- 53G 71W AAYXX ACCJW ADFPA ADGHP ADNKB AE3 AEETU AFFNX AHJKT AHRYX AJNYG BS7 C1A CITATION DUNZO EJD FW0 H13 J5H JF9 JG8 N~M OCUKA ODA ORVUJ OUVQU OWU OWV OWX OWZ P-K T8P X7M XXN XYM ZGI ZZMQN ACIJW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c3958-b7c9ddd0b55cfada27cc6d77f02a88c2085ce8bdddf2ed0d1c81cd1cfc1dbca33 |
ISSN | 1079-5642 1524-4636 |
IngestDate | Thu Jul 10 20:02:29 EDT 2025 Thu Apr 03 07:06:48 EDT 2025 Tue Jul 01 00:38:34 EDT 2025 Thu Apr 24 23:10:21 EDT 2025 Fri May 16 03:49:46 EDT 2025 Fri May 16 03:51:37 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | matrix metalloprotease galectin 1 aorta cytokines incidence aortic aneurysm, abdominal |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3958-b7c9ddd0b55cfada27cc6d77f02a88c2085ce8bdddf2ed0d1c81cd1cfc1dbca33 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-7414-6358 0000-0001-6832-3234 0000-0002-6316-2328 |
PMID | 33147994 |
PQID | 2457967959 |
PQPubID | 23479 |
PageCount | 15 |
ParticipantIDs | proquest_miscellaneous_2457967959 pubmed_primary_33147994 crossref_citationtrail_10_1161_ATVBAHA_120_315398 crossref_primary_10_1161_ATVBAHA_120_315398 wolterskluwer_health_10_1161_ATVBAHA_120_315398 wolterskluwer_health_00043605-202101000-00032 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-January-01 |
PublicationDateYYYYMMDD | 2021-01-01 |
PublicationDate_xml | – month: 01 year: 2021 text: 2021-January-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Arteriosclerosis, thrombosis, and vascular biology |
PublicationTitleAlternate | Arterioscler Thromb Vasc Biol |
PublicationYear | 2021 |
Publisher | Lippincott Williams & Wilkins American Heart Association, Inc |
Publisher_xml | – name: Lippincott Williams & Wilkins – name: American Heart Association, Inc |
References | e_1_3_4_3_2 e_1_3_4_2_2 e_1_3_4_9_2 e_1_3_4_8_2 e_1_3_4_7_2 e_1_3_4_41_2 e_1_3_4_6_2 e_1_3_4_40_2 e_1_3_4_5_2 e_1_3_4_4_2 e_1_3_4_22_2 e_1_3_4_45_2 e_1_3_4_23_2 e_1_3_4_44_2 e_1_3_4_20_2 e_1_3_4_43_2 e_1_3_4_21_2 e_1_3_4_42_2 e_1_3_4_26_2 e_1_3_4_27_2 e_1_3_4_48_2 e_1_3_4_24_2 e_1_3_4_47_2 e_1_3_4_25_2 e_1_3_4_46_2 e_1_3_4_28_2 e_1_3_4_29_2 Cummings RD (e_1_3_4_14_2) 2009 e_1_3_4_30_2 e_1_3_4_11_2 e_1_3_4_34_2 e_1_3_4_12_2 e_1_3_4_33_2 e_1_3_4_32_2 e_1_3_4_10_2 e_1_3_4_31_2 e_1_3_4_15_2 e_1_3_4_38_2 e_1_3_4_16_2 e_1_3_4_37_2 e_1_3_4_13_2 e_1_3_4_36_2 e_1_3_4_35_2 e_1_3_4_19_2 e_1_3_4_17_2 e_1_3_4_18_2 e_1_3_4_39_2 |
References_xml | – ident: e_1_3_4_38_2 doi: 10.1073/pnas.1609019113 – ident: e_1_3_4_8_2 doi: 10.1161/01.ATV.0000143384.69170.2d – ident: e_1_3_4_46_2 doi: 10.1371/journal.pone.0001774 – ident: e_1_3_4_25_2 doi: 10.1073/pnas.0603883103 – ident: e_1_3_4_39_2 doi: 10.1016/j.ajpath.2012.09.022 – ident: e_1_3_4_12_2 doi: 10.1042/CS20030189 – ident: e_1_3_4_19_2 doi: 10.1093/glycob/cwu008 – ident: e_1_3_4_13_2 doi: 10.4049/jimmunol.0803164 – ident: e_1_3_4_17_2 doi: 10.1016/S0021-9258(19)50024-2 – ident: e_1_3_4_32_2 doi: 10.1161/01.atv.20.12.2527 – ident: e_1_3_4_48_2 doi: 10.1161/ATVBAHA.110.206573 – ident: e_1_3_4_15_2 doi: 10.1016/s0304-4165(02)00313-6 – ident: e_1_3_4_22_2 doi: 10.1523/JNEUROSCI.4483-03.2004 – ident: e_1_3_4_21_2 doi: 10.4049/jimmunol.1701172 – ident: e_1_3_4_4_2 doi: 10.1111/febs.13634 – ident: e_1_3_4_30_2 doi: 10.1016/j.jvs.2006.04.047 – ident: e_1_3_4_26_2 doi: 10.1159/000025625 – ident: e_1_3_4_28_2 doi: 10.1038/s41598-018-29843-3 – ident: e_1_3_4_33_2 doi: 10.1007/BF02978209 – ident: e_1_3_4_44_2 doi: 10.1101/cshperspect.a011254 – ident: e_1_3_4_42_2 doi: 10.1038/sj.onc.1204950 – ident: e_1_3_4_31_2 doi: 10.3389/fphar.2010.00009 – ident: e_1_3_4_40_2 doi: 10.1152/ajplung.00192.2006 – ident: e_1_3_4_23_2 doi: 10.1016/j.imlet.2010.03.010 – ident: e_1_3_4_9_2 doi: 10.1172/JCI38308 – ident: e_1_3_4_47_2 doi: 10.1016/j.biopha.2009.09.008 – ident: e_1_3_4_11_2 doi: 10.1161/CIRCRESAHA.112.270520 – ident: e_1_3_4_24_2 doi: 10.1126/science.6367039 – ident: e_1_3_4_10_2 doi: 10.1016/j.jtcvs.2011.07.053 – ident: e_1_3_4_43_2 doi: 10.1074/jbc.M205698200 – ident: e_1_3_4_20_2 doi: 10.1016/s1471-4906(02)02232-9 – volume-title: In: Essentials of Glycobiology year: 2009 ident: e_1_3_4_14_2 – ident: e_1_3_4_29_2 doi: 10.1161/01.ATV.0000085631.76095.64 – ident: e_1_3_4_45_2 doi: 10.1161/01.CIR.0000058700.41738.12 – ident: e_1_3_4_5_2 doi: 10.1016/j.ejvs.2005.10.030 – ident: e_1_3_4_18_2 doi: 10.1046/j.1432-1033.2000.01311.x – ident: e_1_3_4_16_2 doi: 10.1093/glycob/cwl025 – ident: e_1_3_4_3_2 doi: 10.1146/annurev-med-101712-174206 – ident: e_1_3_4_41_2 doi: 10.1038/s41598-018-22135-w – ident: e_1_3_4_6_2 doi: 10.1161/01.ATV.0000214999.12921.4f – ident: e_1_3_4_34_2 doi: 10.1165/ajrcmb.23.1.4014 – ident: e_1_3_4_27_2 doi: 10.1016/s0008-6363(99)00276-x – ident: e_1_3_4_35_2 doi: 10.1165/ajrcmb.20.4.3420 – ident: e_1_3_4_2_2 doi: 10.1056/NEJMcp1401430 – ident: e_1_3_4_7_2 doi: 10.1038/nrcardio.2017.52 – ident: e_1_3_4_37_2 doi: 10.1291/hypres.30.1015 – ident: e_1_3_4_36_2 doi: 10.1161/01.CIR.0000165117.71483.0C |
SSID | ssj0004220 |
Score | 2.4516435 |
Snippet | OBJECTIVE:Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless,... Abdominal aortic aneurysm (AAA) is a vascular degenerative disease causing sudden rupture of aorta and significant mortality in elders. Nevertheless, no... |
SourceID | proquest pubmed crossref wolterskluwer |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 331 |
SubjectTerms | Adventitia - metabolism Adventitia - pathology Angiotensin II Animals Aorta, Abdominal - metabolism Aorta, Abdominal - pathology Aortic Aneurysm, Abdominal - chemically induced Aortic Aneurysm, Abdominal - metabolism Aortic Aneurysm, Abdominal - pathology Aortitis - chemically induced Aortitis - metabolism Aortitis - pathology Case-Control Studies Cells, Cultured Cytokines - metabolism Disease Models, Animal Disease Progression Extracellular Matrix - metabolism Extracellular Matrix - pathology Fibroblasts - metabolism Fibroblasts - pathology Galectin 1 - blood Galectin 1 - deficiency Galectin 1 - genetics Galectin 1 - metabolism Humans Inflammation Mediators - metabolism Macrophages, Peritoneal - metabolism Macrophages, Peritoneal - pathology Male Matrix Metalloproteinase 9 - metabolism Mice Mice, Inbred C57BL Mice, Knockout, ApoE Mitogen-Activated Protein Kinases - metabolism Muscle, Smooth, Vascular - metabolism Muscle, Smooth, Vascular - pathology Myocytes, Smooth Muscle - metabolism Myocytes, Smooth Muscle - pathology Signal Transduction Up-Regulation Vascular Remodeling |
Title | Gal-1 (Galectin-1) Upregulation Contributes to Abdominal Aortic Aneurysm Progression by Enhancing Vascular Inflammation |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-202101000-00032 https://www.ncbi.nlm.nih.gov/pubmed/33147994 https://www.proquest.com/docview/2457967959 |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAIIe4rNxmJB1DlLc49jwFtdKAiIbXTeIoc2xnV1mRaGk3jh_B7OSdO0mwdE-MlalPHdft9iX2Oz_kOIe88JVylbMlkxhVzgRVMSIFRVq6MbDA5dJ1IO_nmj2fulwPvYDD43Ytaqpbplvx1ZV7J_6AK5wBXzJK9AbJdp3ACXgO-cASE4fhPGH8Wx4zXhr5A7_s8Zxyt_NnJqakwj9Ci_FRd1MpoOcSpKkwdr7jADkcxKlqelwtMGTg0QbE5rkl38p8oxZEfjvbbYNW9PAP-LFZYduq1KPhclDA6mHONaAGWX1ik7Tv0zncxr43u0yqwYN74rCfwbWxaivnqI_NQ3GOTdoZFBpZVveSu2K5ea_pD52xczfvODJtfcmZ0u1RjuM2XfYauRYaC2RoxzzfSXOvzgI_zQDzd_xiP0d-LvgnPMfWuL-lrX9f8Frltg_mBlTG-fu-p0Nu2UblohtAmY_l8e72PiwueNSvmHrl_VmBgRHlU50X0VjfTh-RBY5bQ2HDsERno_DG5M2kCL56Qs5pq9P2KaB9on2a0RzO6LGhHM2poRlua0R7NaHpOO5rRlma0T7OnZLa7M_00Zk3NDiadyAtZGshIKWWlniczoYQdSOmrIMgsW4ShxIqwUocpNMlsrSzFZcglHDPJVSqF4zwjG3mR601CIx8Wr1L7ViosN8iC0MqUllrUJoP27CHh7R-byEbQHuuqHCe1YevzpAEjATASA8aQjLprToycy7Wt37Z4JfDUxa00keuiKhPbxRzuIPKiIXlugOz6cxzuBlHkDgm7gGxiMpuTevfdtzyGN4DFG2kHB37P9pXt_z6-Fze-4iW5u7rtXpGN5WmlX8Oqepm-qSn-B1Y1yQw |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gal-1+%28Galectin-1%29+Upregulation+Contributes+to+Abdominal+Aortic+Aneurysm+Progression+by+Enhancing+Vascular+Inflammation&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Chiang%2C+Ming-Tsai&rft.au=Chen%2C+I-Ming&rft.au=Hsu%2C+Fu-Fei&rft.au=Chen%2C+Yen-Hui&rft.date=2021-01-01&rft.pub=American+Heart+Association%2C+Inc&rft.issn=1079-5642&rft_id=info:doi/10.1161%2FATVBAHA.120.315398&rft.externalDocID=10.1161%2FATVBAHA.120.315398 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon |